한국어
English
日本語
中文(简体)Tecvayli 153mg (Teclistamab)
153mg
Injections · Prescription medication
Janssen Korea Co., Ltd.
Teclistamab is an immunomodulatory anticancer agent used in the treatment of multiple myeloma.
MFDS ingredient code M283888
Teclistamab is a bispecific antibody used for the treatment of multiple myeloma, capable of recognizing both T cells of the immune system and cancer cells simultaneously to exhibit anticancer effects. This ingredient belongs to the class of immunomodulators and helps activate the patient's immune response to attack cancer cells.
Teclistamab binds simultaneously to the CD3 protein on T cells and the BCMA protein on multiple myeloma cells. This induces T cells to recognize and attack cancer cells, promoting an immune response that removes cancer cells.
Approved uses differ by product. Check each product's information for its actual use.
As a bispecific antibody, Teclistamab is characterized by its ability to recognize two different proteins at the same time, unlike monoclonal antibodies that target a single protein. This allows for a more effective connection of immune cells to cancer cells, enhancing therapeutic efficacy.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.